The survival effect of prolactin on PC3 prostate cancer cells

European Urology

Volumn 43, Issue 3, 2003, Pages 301-308

  Ruffion, Alain ^a   Al Sakkaf, Kaltoom A ^b   Brown, Barry L ^b   Eaton, Colby L ^b   Hamdy, Freddie C ^b   Dobson, Pauline R M ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Akt; Apoptosis; Prolactin; Prostate cancer; TRAIL

Indexed keywords

FLAVOPIRIDOL; LIPOCORTIN 5; PROLACTIN; PROLACTIN RECEPTOR; PROTEIN KINASE B; STAUROSPORINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; COULTER COUNTER; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MICROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 0037338576     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00038-1     Document Type: Conference Paper

References (43)

1. Huggins C, Russell P. Quantitative effects on hypophysectomy on testis and prostate of dogs. Endocrinology 1946;39:1-7.
2. Grayhack J. Pituitary factor influencing growth of the prostate. NCI Monogr 1963;12:189-99.
3. Negro-Vilar A, Saad WA, McCann SM. Evidence for a role of prolactin in prostate and seminal vesicle growth in immature male rats. Endocrinology 1977;100:729-37.
4. Reiter E, Hennuy B, Bruyninx M, Cornet A, Klug M, McNamara M, et al. Effects of pituitary hormones on the prostate. Prostate 1999;38:159-65.
5. Wennbo H, Kindblom J, Isaksson OG, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997;138:4410-5.
6. Van Coppenolle F, Slomianny C, Carpentier F, Le Bourhis X, Ahidouch A, Croix D, et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgen-dependence. Am J Physiol Endocrinol Metab 2001;280:E120-9 [in process citation].
7. Prins GS. Prolactin influence on cytosol and nuclear androgen receptors in the ventral, dorsal, and lateral lobes of the rat prostate. Endocrinology 1987;120:1457-64.
8. Farnsworth WE. Prolactin effect on the permeability of human benign hyperplastic prostate to testosterone. Prostate 1988;12:221-9.
9. Davies P, Eaton CL. Regulation of prostate growth. J Endocrinol 1991;131:5-17.
10. Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncol Rep 1998;5:893-6.
11. Huhtaniemi I, Parvinen M, Venho P, Rannikko S. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects. Int J Androl 1991;14:374-86.
12. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999;80:930-4.
13. Vijayakumar S, Quadri SF, Dong L, Ignacio L, Kathuria IN, Sutton H, et al. Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J Natl Med Assoc 1995;87:813-9.
14. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2:27-32.
15. Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, et al. Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer 2001;92:463-5.
16. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996;17:639-69.
17. Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 1999;154:863-70.
18. Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 1999;140:5412-21.
19. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997;99: 618-27.
20. Lane KE, Leav I, Ziar J, Bridges RS, Rand WM, Ho SM. Suppression of testosterone and estradiol-17beta-induced dysplasia in the dorsolateral prostate of Noble rats by bromocriptine. Carcinogenesis 1997;18:1505-10.
21. de la Taille A, Chen MW, Burchardt M, Chopin DK, Buttyan R. Apoptotic conversion: evidence for exchange of genetic information between prostate cancer cells mediated by apoptosis. Cancer Res 1999;59:5461-3.
22. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
23. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276: 10767-74.
24. Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, et al. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene 2001;20:3757-65.
25. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/ tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001;61:759-63.
26. Srinivasula SM, Ahmad M, Femandes-Alnemri T, Litwack G, Alnemri ES. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci USA 1996;93:14486-91.
27. Rokhlin OW, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res 1998;58:5870-5.
28. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998;91:458-65.
29. Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y. Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 1994;211:314-21.
30. Costello LC, Liu Y, Zou J, Franklin RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J Biol Chem 1999;274:17499-504.
31. Costello LC, Liu Y, Zou J, Franklin RB. The pyruvate dehydrogenase E1 alpha gene is testosterone and prolactin regulated in prostate epithelial cells. Endocr Res 2000;26:23-39.
32. Untergasser G, Rumpold H, Hermann M, Dirnhofer S, Jilg G, Berger P. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Exp Gerontol 1999;34:275-87.
33. Xu X, Kreye E, Kuo CB, Walker AM. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res 2001;61:6098-104.
34. Peirce SK, Chen WY. Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J Endocrinol 2001;171:R1-4.
35. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, et al. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer 1996;77:144-9.
36. Al-Sakkaf KA, Mooney LM, Dobson PRM, Brown BL. Possible role for protein kinase B in the anti-apoptotic effect of prolactin in rat Nb2 lymphoma cells. J Endocrinol 2000;167:85-92.
37. Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995;267:2003-6.
38. Al-Sakkaf KA, Dobson PRM, Brown BL. Activation of phosphatidylinositol 3-kinase by prolactin in Nb2 cells. Biochem Biophys Res Commun 1996;221:779-84.
39. Al-Sakkaf KA, Dobson PRM, Brown BL. Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells. J Mol Endocrinol 1997;19:347-50.
40. Cohen P, Alessi DR, Cross DA. PDK1, one of the missing links in insulin signal transduction? FEBS Lett 1997;410:3-10.
41. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
42. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, et al. Prosurvival function of Akt/protein kinase B in prostate cancer cells: relationship with TRAIL resistance. J Biol Chem 2001;276: 38361-9.
43. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073-83.